FY2016
Effective from
- First observed
Multiple endocrine neoplasia [MEN] syndromes
Category — select a more specific code
CDC/NCHS · FY2016any associated malignancies and other conditions associated with the syndromes
For US diagnosis claims covered by HIPAA, ICD-10-CM is required from October 1, 2015.
Use the service date for outpatient/professional claims and the discharge date for hospital inpatient claims. Earlier encounters use ICD-9-CM; each individual code must also be valid for the applicable date.
Official coding guidelines → · CMS ↗First observed · 2015-10-01
No recorded change since first observation
Effective from
Multiple endocrine neoplasia [MEN] syndromes
Category — select a more specific code
CDC/NCHS · FY2016| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Multiple endocrine adenomatosis
any associated malignancies and other conditions associated with the syndromes
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Other entries in the same category; these are not automatic substitutes.
| Code | Description | Category · further specificity required |
|---|---|---|
| E31.0 | Autoimmune polyglandular failure | Billable / specific |
| E31.1 | Polyglandular hyperfunction | Billable / specific |
| E31.8 | Other polyglandular dysfunction | Billable / specific |
| E31.9 | Polyglandular dysfunction, unspecified | Billable / specific |
Official titles and instructions are preserved in their source language. Official sources ↗
Code also · any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Code also · any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Excludes 1 · multiple endocrine adenomatosis (E31.2-)
Excludes 1 · multiple endocrine neoplasia (E31.2-)
Excludes 1 · multiple endocrine adenomatosis (E31.2-)
Excludes 1 · multiple endocrine neoplasia (E31.2-)
Excludes 2 · multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Excludes 1 · multiple endocrine neoplasia [MEN] syndromes (E31.2-)